We use cookies for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.
Add this topic to your myFT Digest for news straight to your inbox
Some on vaccine committee take cautious line over blood clots, while others fear impact on inoculation rollout
Researchers hope to counter scepticism about the value of lateral flow tests
Creation of task force by UK government welcomed but no trials have delivered solutions
Pharma is concerned that Katherine Tai is considering granting a Trips waiver for Covid vaccines and treatments
Swiss pharmaceutical company reports 55% jump in diagnostic sales
Although infections are at a record high, lives are being saved in countries with effective immunisation programmes
Washington can boost global access to Covid shots by compelling technology sharing, says top NIH scientist
New variant suspected of stoking surge that is overwhelming hospitals and crematoriums
European Medicines Agency says jab’s benefits still outweigh risks despite blood clot concerns
Antivirals task force will seek to develop medicines people can take at home
Rapid acquisitions are transforming the animal care sector but also prompting a political backlash
Scientists probe whether adenoviral vectors in AstraZeneca and J&J shots are triggering rare reaction
It has quietly built up a multibillion-dollar stake in the struggling drugmaker
Johnson & Johnson, Teva, Endo and Allergan face latest test in legal fallout from epidemic
Boris Johnson cancels trip as authorities lock down Delhi and restrict oxygen use in battle with new variant
Fermentation and ‘good bacteria’ are beauty’s new buzz ingredients. We look at the yeast you can do
Company can pursue beneficial acquisition roll-up strategy in highly fragmented market
Rebuilding trust may take time after blood clot concerns with adenovirus-based jab
Bill for taxpayers continues long after those in care become adults because of system faults, study shows
The chief cannot be rewarded for good things and not be held accountable for the bad things
Rome’s talks with manufacturers come as EU seems to be moving away from AstraZeneca and J&J
Manufacturers consider withdrawing up to 90% of medicines they currently send to region
International Edition
